natgillin/translations-raw huggingface dataset:
If bullous pemphigoid is suspected, Jentadueto should be discontinued. 
Če obstaja sum na bulozni pemfigoid, je treba zdravjenje z zdravilom Jentadueto ukiniti.
You should not exceed the maximum recommended daily dose of 5 mg linagliptin and 2,000 mg metformin hydrochloride. 
Največjega priporočenega dnevnega odmerka, ki je 5 mg linagliptina in 2000 mg metforminijevega klorida, ne smete prekoračiti.
Metformin hydrochloride stimulates intracellular glycogen synthesis by acting on glycogen synthase. 
Z delovanjem na glikogen-sintazo metforminijev klorid spodbuja intracelularno sintezo glikogena.
In a cardiovascular and renal safety study (CARMELINA) with median observation period of 2.2 years, adjudicated acute pancreatitis was reported in 0.3% of patients treated with linagliptin and in 0.1% of patients treated with placebo. 
V študiji o srčno-žilni in ledvični varnosti (CARMELINA), z mediano obdobja opazovanja 2,2 leti, je bilo ugotovljeno, da so o akutnem pankreatitisu poročali pri 0,3 % bolnikov, zdravljenih z linagliptinom, in pri 0,1 % bolnikov, zdravljenih s placebom.
Linagliptin 5 mg showed superiority over 1 mg with regard to trough DPP-4 inhibition (72% vs 32%, p=0.0050) and a numerically larger reduction with regard to adjusted mean change from baseline in HbA1c (-0.63% vs -0.48%, n.s.). 
Linagliptin 5 mg je pokazal superiornost nad 1 mg odmerkom pri najnižjem zaviranju DPP-4 (72 % v primerjavi z 32 %, p = 0,0050) in številčno večje zmanjšanje prilagojene spremembe mediane glede na izhodiščno vrednost HbA1c (-0,63 % v primerjavi z -0,48 %, »ni statistično značilno«).
INFORMATION IN BRAILLE Jentadueto 2.5 mg/1,000 mg 
PODATKI V BRAILLOVI PISAVI Jentadueto 2,5 mg/1000 mg
The efficacy and safety of linagliptin in combination with metformin in patients with insufficient glycaemic control on metformin monotherapy was evaluated in a double-blind placebo-controlled study of 24 weeks duration. 
Učinkovitost in varnost linagliptina v kombinaciji z metforminom so pri bolnikih z nezadostno urejeno glikemijo med monoterapijo z metforminom ocenili v dvojno slepi, s placebom nadzorovani 24-tedenski študiji.
In the pooled analysis of the seven placebo-controlled trials, the overall incidence of adverse events in patients treated with placebo and metformin was comparable to that seen with linagliptin 2.5 mg and metformin (54.3 and 49.0%). 
V analizi zbranih podatkov iz sedmih s placebom nadzorovanih preskušanj je bila skupna pojavnost neželenih dogodkov pri bolnikih, ki so jemali placebo in metformin, primerljiva z njihovo pojavnostjo pri tistih, ki so jemali po 2,5 mg linagliptina in metformin (54,3 % in 49,0 %).
Some patients have had the following side effects while taking Jentadueto: - Common (may affect up to 1 in 10 people): diarrhoea, blood enzyme increase (lipase increase), 
Pri nekaterih bolnikih so se med jemanjem zdravila Jentadueto pojavili naslednji neželeni učinki: - Pogosti (pojavijo se lahko pri do 1 od 10 bolnikov): driska, zvišana raven encima v krvi
Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 
Metformin je treba pred slikanjem ali v času slikanja ukiniti in se ga sme ponovno uvesti najmanj 48 ur pozneje, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno, glejte poglavji 4.2 in 4.5.
You should not use Jentadueto if you are pregnant. 
Če ste noseči, zdravila Jentadueto ne smete uporabljati.
In the treated population, severe hypoglycaemic events (requiring assistance) were reported in 3.0% of patients on linagliptin and in 3.1% on placebo. 
Pri zdravljeni populaciji so o hudih hipoglikemičnih dogodkih (kjer je bila potrebna pomoč) poročali pri 3,0 % bolnikov, ki so jemali linagliptin, in pri 3,1 % bolnikov, ki so jemali placebo.
Among patients who were using sulfonylurea at baseline, the incidence of severe hypoglycaemia was 2.0% in linagliptin-treated patients and 1.7% in placebo treated patients. 
Med bolniki, ki so ob izhodišču jemali sulfonilsečnino, je bila pojavnost hude hipoglikemije 2,0 % pri bolnikih, ki so se zdravili z linagliptinom, in 1,7 % pri bolnikih, ki so se zdravili s placebom.
The most frequently reported adverse reaction for linagliptin plus metformin was diarrhoea (1.6%) with a comparable rate on metformin plus placebo (2.4%). 
Najpogostnejši neželeni učinek, o katerem so poročali pri kombinaciji linagliptina z metforminom, je bil driska (1,6 %), katerega razmerje je bilo podobno kot pri kombinaciji metformina in placeba
- The active substances are linagliptin and metformin hydrochloride. 
- Učinkovini sta linagliptin in metforminijev klorid.
How to take Jentadueto 
Kako jemati zdravilo Jentadueto
Clinically meaningful interactions would not be expected with other sulphonylureas (e.g., glipizide, tolbutamide, and glimepiride) which, like glibenclamide, are primarily eliminated by CYP2C9. 
Pri drugih sulfonilsečninah (npr. glipizidu, tolbutamidu in glimepiridu), ki se tako kot glibenklamid primarno izločajo prek CYP2C9, predvidoma ne prihaja do klinično pomembnih interakcij.
It is especially important to mention the following: - medicines which increase urine production (diuretics) - medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib) - certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II 
Posebno pomembno je omeniti naslednje: - zdravila, ki povečajo nastajanje urina (diuretiki), - zdravila za zdravljenje bolečine in vnetja (nesteroidna protivnetna zdravila in zaviralci COX-2,
Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in the elderly (see sections 4.3 and 4.4). 
Da bi, zlasti pri starejših, preprečili z metforminom povezano laktacidozo, je treba bolnikom spremljati ledvično delovanje (glejte poglavji 4.3 in 4.4).
isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration. 
lahko zmanjša izločanje metformina skozi ledvice, kar lahko vodi v povečanje koncentracije metformina v plazmi;
No dose adjustment of linagliptin is recommended in patients with renal impairment; therefore, linagliptin may be continued as a single entity tablet at the same total daily dose of 5 mg if Jentadueto is discontinued due to evidence of renal impairment. 
Zdravljenje z linagliptinom se lahko nadaljuje z eno tableto pri enakem skupnem dnevnem odmerku po 5 mg, če zdravilo Jentadueto ukinemo zaradi znakov ledvične okvare.
trimethoprime, vandetanib, isavuconazole, crizotinib, olaparib). 
cimetidin, dolutegravir, ranolazin, trimetoprim, vandetanib, izavukonazol, krizotinib, olaparib),
Linagliptin is a P-glycoprotein substrate, and inhibits P-glycoprotein mediated transport of digoxin with low potency. 
Linagliptin je substrat za P-glikoprotein in šibko zavira prenos digoksina, ki ga posreduje P-glikoprotein.
- Pack sizes of 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets and multipacks containing 120 (2 packs of 60 x 1), 180 (2 packs of 90 x 1) and 200 (2 packs of 100 x 1) film-coated tablets in aluminium lidding foil and PVC/polychlorotrifluoro ethylene/PVC based forming foil perforated unit dose blisters. 
- Velikosti pakiranja po 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 in 120 x 1 filmsko obložena tableta in večkratna pakiranja po 120 (2 enoti po 60 x 1), 180 (2 enoti po 90 x 1) in 200 (2 enoti po 100 x 1) filmsko obloženih tablet v perforiranih enoodmernih pretisnih omotih iz aluminijaste pokrivne folije in PVC/poliklortrifluoroetilen/PVC osnovne folije.
In one study linagliptin was given as add-on to metformin plus sulphonylurea. 
V eni od študij je bil metforminu in sulfonilsečnini dodan linagliptin.
Under steady-state conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy subjects. 
V stanju dinamičnega ravnovesja je bila izpostavljenost linagliptinu pri bolnikih z blago ledvično okvaro primerljiva izpostavljenosti pri zdravih preizkušancih.
Caution should be exercised in patients with a history of pancreatitis. 
Pri bolnikih s pankreatitisom v anamnezi je potrebna previdnost.
Linagliptin also showed significant improvements in patients achieving a target HbA1c of < 7.0% (31.2% on linagliptin versus 9.2% on placebo), and also for fasting plasma glucose (FPG) with -12.7 mg/dl reduction compared to placebo. 
Pomembno je izboljšal tudi doseganje ciljne ravni HbA1c, in sicer na < 7,0 % (31,2 % pri linagliptinu v primerjavi z 9,2 % pri placebu) ter raven glukoze v plazmi na tešče, z zmanjšanjem za -12,7 mg/dl v primerjavi s placebom.
The observed incidence of hypoglycaemia in patients treated with linagliptin was similar to placebo. 
Pojavnost hipoglikemije je bila pri bolnikih, ki so se zdravili z linagliptinom, podobna kot pri placebu.
Patients switching from co-administration of linagliptin and metformin For patients switching from co-administration of linagliptin and metformin, Jentadueto should be initiated at the dose of linagliptin and metformin already being taken. 
Bolniki, ki so do zamenjave zdravila sočasno jemali linagliptin in metformin Bolnikom, ki so do zamenjave zdravila sočasno jemali linagliptin in metformin, je treba zdravljenje začeti z enakima odmerkoma teh dveh zdravil, kot so ju jemali dotlej.
In the overall study observation period adjudicated acute pancreatitis was reported in 0.3% of patients treated with linagliptin and in 0.1% of patients treated with placebo. 
V celotnem obdobju študijskega opazovanja je bilo ugotovljeno, da so o akutnem pankreatitisu poročali pri 0,3 % bolnikov, ki so se zdravili z linagliptinom, in 0,1 % bolnikov, ki so se zdravili s placebom.
The NOAEL for maternal-, embryo-fetal-, and offspring toxicity in rats was 49 times human exposure. 
Odmerek, pri katerem še ni opaziti toksičnega učinka (NOAEL) na samice, zarodke in plodove ter potomce pri podganah, je bil 49-krat večji od izpostavljenosti za človeka.
Co-administration with 5 mg linagliptin did not alter the steady-state pharmacokinetics of levonorgestrel or ethinylestradiol. 
Pri sočasnem jemanju 5 mg linagliptina se farmakokinetika levonorgestrela ali etinilestradiola v stanju dinamičnega ravnovesja ni spremenila.
The steady-state pharmacokinetics of 5 mg linagliptin were not changed by concomitant administration of a single 1.75 mg dose glibenclamide (glyburide). 
V stanju dinamičnega ravnovesja se farmakokinetika linagliptina po 5 mg odmerku pri sočasnem dajanju enkratnega odmerka po 1,75 mg glibenklamida (gliburida) ni spremenila.
Co-administration of multiple doses of linagliptin and metformin did not meaningfully alter the pharmacokinetics of either linagliptin or metformin in healthy volunteers and patients. 
Sočasno dajanje večkratnih odmerkov linagliptina in metformina niti pri zdravih prostovoljcih niti bolnikih ni pomembneje spremenilo njune farmakokinetike.
Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis. 
Pri akutnem poslabšanju delovanja ledvic se začne metformin kopičiti, kar poveča tveganje za laktacidozo.
Metformin is excreted in human milk in small amounts. 
Pri ljudeh se v mleko izloča majhna količina metformina.
• a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patientyears (p=0.021), 
• pomembno zmanjšanje absolutnega tveganja celokupne umrljivosti: metformin 13,5 dogodka/1000 bolnikovih let v primerjavi s samo dieto 20,6 dogodka/1000 bolnikovih let (p = 0,011), in v primerjavi z združenima skupinama na monoterapiji s sulfonilsečnino in insulinom, 18,9 dogodka/1000 bolnikovih let (p = 0,021).
• a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017, 
• pomembno zmanjšanje absolutnega tveganja za katerikoli s sladkorno boleznijo povezan usodni izid: metformin 7,5 dogodka/1000 bolnik let, samo dieta 12,7 dogodka/1000 bolnikovih let, p = 0,017;
After a median follow up of 6.25 years, linagliptin, when added to standard of care, did not increase the risk of major adverse cardiovascular events (table 5) as compared to glimepiride. 
Linagliptin, kadar je bil dodan standardni terapiji, v primerjavi z glimepiridinom ni povečal tveganja za hude neželene srčno-žilne dogodke po mediani spremljanja 6,25 let (glejte preglednico 5).
In a pooled analysis of elderly (age ≥ 70 years) patients with type 2 diabetes (n=183) who were taking both metformin and basal insulin as background therapy, linagliptin in combination with metformin plus insulin provided significant improvements in HbA1c parameters with -0.81% (CI: -1.01; -0.61) adjusted mean change from baseline (mean baseline HbA1c 8.13%) compared to placebo in combination with metformin plus insulin. 
V analizi združenih podatkov o starejših bolnikih (starost ≥ 70 let) s sladkorno boleznijo tipa 2 (n = 183), ki so za osnovno zdravljenje jemali metformin in bazalni insulin, je linagliptin v kombinaciji z metforminom in insulinom v primerjavi s placebom v kombinaciji z metforminom in insulinom pomembno izboljšal parametre HbA1c, saj je bila prilagojena srednja sprememba v primerjavi z izhodiščno ravnijo (srednja izhodiščna raven HbA1c 8,13 %) -0,81 % (IZ: -1,01; -0,61).
Therefore, linagliptin is not an inhibitor of P-glycoprotein-mediated transport in vivo. 
Torej linagliptin ne zavira s P-glikoproteinom posredovanega prenosa in vivo.
The dose of Jentadueto should provide linagliptin dosed as 2.5 mg twice daily (5 mg total daily dose) and a dose of metformin similar to the dose already being taken. 
Z odmerkom zdravila Jentadueto morajo bolniki prejeti po 2,5 mg linagliptina dvakrat na dan (skupni dnevni odmerek je 5 mg) in podoben odmerek metformina, kot so ga že jemali.
Maximum daily dose is 1000 mg. 
30 do 44 Največji dnevni odmerek je 1.000 mg.
Co-administration of multiple daily doses of 5 mg linagliptin with multiple doses of 0.25 mg digoxin had no effect on the pharmacokinetics of digoxin in healthy subjects. 
Sočasno dajanje večkratnih dnevnih odmerkov linagliptina po 5 mg in večkratnih odmerkov digoksina po 0,25 mg pri zdravih prostovoljcih ni vplivalo na farmakokinetiko digoksina.
• a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01). 
• pomembno zmanjšanje absolutnega tveganja pojava miokardnega infarkta: metformin 11 dogodkov/1000 bolnikovih let, sama dieta 18 dogodkov/1000 bolnikovih let, (p = 0,01).
Co-administration of multiple daily doses of 10 mg linagliptin with 850 mg metformin hydrochloride, an OCT substrate, had no relevant effect on the pharmacokinetics of metformin in healthy subjects. 
Sočasno dajanje večkratnih dnevnih odmerkov linagliptina po 10 mg z 850 mg metforminijevega klorida, substrata za OCT, pri zdravih prostovoljcih ni relevantno vplivalo na farmakokinetiko metformina.
Risk of lactic acidosis. 
Tveganje za laktacidozo
Multiple co-administration of 5 mg linagliptin with rifampicin, a potent inductor of P-glycoprotein and CYP3A4, resulted in a 39.6% and 43.8% decreased linagliptin steady-state AUC and Cmax respectively, and about 30% decreased DPP-4 inhibition at trough. 
Po večkratnem sočasnem dajanju linagliptina po 5 mg in rifampicina, močnega induktorja P-glikoproteina in CYP3A4, sta se za 39,6 % in 43,8 % zmanjšali AUC in Cmax linagliptina v stanju dinamičnega ravnovesja ter za približno 30 % zaviralni učinek na DPP-4 pri najmanjši koncentraciji v plazmi.
Oval, biconvex, light pink, film-coated tablet of 21.1 mm x 9.7 mm debossed with ”D2/1000" on one side and the company logo on the other. 
Jentadueto 2,5 mg/1000 mg filmsko obložene tablete Podolgovata, obojestransko izbočena, svetlo rožnata filmsko obložena tableta velikosti 21,1 mm x 9,7 mm, z vtisnjeno oznako “D2/1000” na eni strani in logotipom podjetja na drugi strani.
What Jentadueto contains 
Kaj vsebuje zdravilo Jentadueto
Description of selected adverse reactions 
Opis določenih neželenih učinkov
Jentadueto is available in perforated unit dose blisters with 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets and multipacks containing 120 x 1 (2 packs of 60 x 1), 180 x 1 (2 packs of 90 x 1) and 200 x 1 (2 packs of 100 x 1) film-coated tablets. 
Zdravilo Jentadueto je na voljo v perforiranih, enoodmernih pretisnih omotih po 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 in 120 x 1 filmsko obložena tableta in večkratnih pakiranjih po 120 x 1 (2 enoti po 60 x 1), 180 x 1 (2 enoti po 90 x 1) in 200 x 1 (2 enoti po 100 x 1) filmsko obložena tableta.
Co-administration of multiple oral doses of 5 mg linagliptin and a single oral dose of 1.75 mg glibenclamide (glyburide) resulted in clinically not relevant reduction of 14% of both AUC and Cmax of glibenclamide. 
Pri sočasnem dajanju večkratnih peroralnih odmerkov linagliptina po 5 mg in enkratnega peroralnega odmerka glibenklamida (gliburida) po 1,75 mg sta se za 14 % zmanjšali AUC in Cmax glibenklamida, kar ni veljalo za klinično pomembno.
A NOAEL of 78 times human exposure was derived for embryo-fetal toxicity in rabbits, and for maternal toxicity the NOAEL was 2.1 times human exposure. 
Odmerek, pri katerem še ni opaziti toksičnega delovanja (NOAEL), so pri kuncih na podlagi toksičnosti za zarodke in plodove določili pri izpostavljenosti, ki 78-krat presega izpostavljenost za človeka, pri samicah pa 2,1-krat.
Co-administration of multiple three-times-daily doses of 850 mg metformin hydrochloride with 10 mg linagliptin once daily did not clinical meaningfully alter the pharmacokinetics of linagliptin in healthy subjects. 
Pri sočasnem dajanju večkratnih odmerkov metforminijevega klorida po 850 mg, trikrat na dan, in 10 mg linagliptina, enkrat na dan, pri zdravih prostovoljcih ni bilo klinično pomembnih sprememb farmakokinetike linagliptina.
This has been shown at therapeutic doses in controlled, medium-term or longterm clinical studies: metformin hydrochloride reduces total cholesterol, LDL cholesterol and triglyceride levels. 
Neodvisno od učinka na glikemijo, metforminijev klorid pri ljudeh ugodno vpliva na presnovo lipidov, kar je bilo dokazano z nadzorovanimi, srednje dolgimi in dolgotrajnimi kliničnimi študijami terapevtskih odmerkov: metforminijev klorid znižuje ravni skupnega holesterola, holesterola LDL in trigliceridov.
System organ class Adverse reaction 
Organski sistem Neželeni učinki
Linagliptin provided significant improvements in HbA1c (-0.64% change compared to placebo after 24 weeks), from a mean baseline HbA1c of 7.8%. 
Linagliptin je pomembno izboljšal HbA1c (-0,64-odstotna sprememba v primerjavi s placebom po 24 tednih), in sicer z izhodiščne ravni HbA1c 7,8 %.
Maximum daily dose is 3000 mg. 
60 do 89 Največji dnevni odmerek je 3.000 mg.
Oval, biconvex, light orange, film-coated tablet of 19.2 mm x 9.4 mm debossed with "D2/850" on one side and the company logo on the other. 
Jentadueto 2,5 mg/850 mg filmsko obložene tablete Podolgovata, obojestransko izbočena, svetlo oranžna filmsko obložena tableta velikosti 19,2 mm x 9,4 mm, z vtisnjeno oznako “D2/850” na eni strani in logotipom podjetja na drugi strani.
Investigations Amylase increased uncommon 
Preiskave povečana raven amilaze občasni povečana raven lipaze*
Factors that may increase the risk of lactic acidosis (see 4.4) should be reviewed before considering initiation of metformin in patients with GFR<60 ml/min. 
Pri bolnikih z GFR < 60 ml/min je treba pred uvedbo metformina pregledati dejavnike, ki lahko povečajo tveganje za laktacidozo (glejte poglavje 4.4).
Age did not have a clinically relevant impact on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. 
Starost ni klinično pomembno vplivala na farmakokinetiko linagliptina, kar je pokazala populacijska farmakokinetična analiza podatkov I. in II faze.
Jentadueto 2.5 mg/850 mg are oval, biconvex, light orange, film-coated tablets (tablets). 
Zdravilo Jentadueto 2,5 mg/850 mg so ovalne, obojestransko izbočene, svetlo oranžne, filmsko obložene tablete (tablete).
Jentadueto 2.5 mg/1,000 mg film-coated tablets also contains iron oxide red (E172). 
Zdravilo Jentadueto 2,5 mg/1000 mg filmsko obložene tablete vsebuje tudi rdeči železov oksid (E172).
• in patients inadequately controlled on their maximally tolerated dose of metformin alone 
• pri bolnikih z nezadostno urejeno boleznijo pri jemanju največjega odmerka metformina, ki ga še prenašajo;
Jentadueto should not be used during pregnancy. 
Zdravila Jentadueto nosečnice ne smejo jemati.
Infections and infestations Nasopharyngitis uncommon 
Infekcijske in parazitske bolezni nazofaringitis občasno
Urticaria rare 
zelo redko
Effects of other medicinal products on linagliptin Clinical data described below suggest that the risk for clinically meaningful interactions by coadministered medicinal products is low. 
Navedeni klinični podatki kažejo na majhno tveganje klinično pomembnih interakcij s sočasno danimi zdravili.
How to take this medicine - one tablet twice daily by mouth in the dose prescribed by your doctor. 
- zaužijte eno tableto dvakrat na dan v odmerku, ki vam ga je predpisal vaš zdravnik; - ob jedi, kar zmanjša možnost pojava želodčnih težav.
Talk to your doctor, pharmacist or nurse before taking Jentadueto - if you have type 1 diabetes (your body does not produce any insulin). 
Pred začetkom jemanja zdravila Jentadueto se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro: - če imate sladkorno bolezen tipa 1 (vaše telo ne izdeluje insulina); zdravila Jentadueto ni dovoljeno uporabljati za zdravljenje tega stanja; - če jemljete insulin ali antidiabetik sulfonilsečnino, vam bo zdravnik morda zmanjšal vaš odmerek insulina ali sulfonilsečnine, če boste katerega od njiju jemali hkrati z zdravilom
PHARMACEUTICAL FORM AND CONTENTS Multipack comprising 2 packs, each containing 60 x 1 film-coated tablets Multipack comprising 2 packs, each containing 90 x 1 film-coated tablets Multipack comprising 2 packs, each containing 100 x 1 film-coated tablets 
FARMACEVTSKA OBLIKA IN VSEBINA Večkratno pakiranje z 2 enotama, ki vsebujeta po 60 x 1 filmsko obloženo tableto.
A delayed time to peak serum concentrations by 2 hours was observed for metformin under fed conditions. 
Pri jemanju s hrano so zasledili tudi podaljšan čas do največje koncentracije v serumu, in sicer za 2 uri.
How Jentadueto works 
Kako deluje zdravilo Jentadueto
Jentadueto 2.5 mg/850 mg film-coated tablets also contains iron oxide red (E172) and iron oxide yellow (E172). 
Zdravilo Jentadueto 2,5 mg/850 mg filmsko obložene tablete vsebuje tudi rdeči (E172) in rumeni železov oksid (E172).
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a sulphonylurea. 
Linagliptin kot dodatno zdravilo ob kombinaciji metformina in sulfonilsečnine Učinkovitost in varnost linagliptina po 5 mg v primerjavi s placebom so ocenili v s placebom nadzorovani 24-tedenski študiji pri bolnikih z nezadostno urejeno boleznijo ob zdravljenju s kombinacijo metformina in sulfonilsečnine.
Body mass index had no clinically relevant effect on the pharmacokinetics of linagliptin based on a population pharmacokinetic analysis of Phase I and Phase II data. 
Indeks telesne mase ni klinično pomembno vplival na farmakokinetiko linagliptina, kar je pokazala populacijska farmakokinetična analiza podatkov I. in II.